The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Discover the groundbreaking AMPLITUDE trial results, showcasing niraparib's effectiveness in treating metastatic prostate cancer with minimal safety concerns.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response ...

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

An expert discusses how combining androgen receptor pathway inhibitors (ARPIs) with PARP inhibitors, particularly ...

Sophia Kamran, MD, discussed the updated AUA guidelines on salvage therapy for patients with prostate cancer and their ...

A groundbreaking telehealth trial offers remote access to innovative pancreatic cancer treatment, enhancing patient ...

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

An expert discusses how treatment decisions in metastatic castration-resistant prostate cancer (mCRPC) increasingly depend on prior androgen receptor pathway inhibitor (ARPI) exposure, highlighting ...